Cargando…
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes v...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242979/ https://www.ncbi.nlm.nih.gov/pubmed/35768576 http://dx.doi.org/10.1038/s41698-022-00291-7 |
_version_ | 1784738190670692352 |
---|---|
author | Dillon, Kasia M. Bekele, Raie T. Sztupinszki, Zsofia Hanlon, Timothy Rafiei, Shahrzad Szallasi, Zoltan Choudhury, Atish D. Mouw, Kent W. |
author_facet | Dillon, Kasia M. Bekele, Raie T. Sztupinszki, Zsofia Hanlon, Timothy Rafiei, Shahrzad Szallasi, Zoltan Choudhury, Atish D. Mouw, Kent W. |
author_sort | Dillon, Kasia M. |
collection | PubMed |
description | PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes varies widely in mCRPC and the impact of the less commonly altered genes on PARP inhibitor sensitivity is uncertain. We used functional approaches to directly test the impact of PALB2 and BARD1 loss on homologous recombination (HR) function and PARP inhibitor sensitivity in prostate cancer cell lines. PALB2 or BARD1 loss led to decreased HR function as measured by loss of radiation-induced Rad51 foci formation as well as decreased HR capacity in a cell-based reporter assay. PALB2 or BARD1 loss also significantly increased sensitivity to the PARP inhibitors olaparib and rucaparib across a panel of prostate cancer cell lines. These data support PALB2 and BARD1 loss as markers of clinically relevant PARP inhibitor sensitivity and highlight the potential to use functional approaches to complement and extend findings from clinical trials of targeted agents. |
format | Online Article Text |
id | pubmed-9242979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92429792022-07-01 PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer Dillon, Kasia M. Bekele, Raie T. Sztupinszki, Zsofia Hanlon, Timothy Rafiei, Shahrzad Szallasi, Zoltan Choudhury, Atish D. Mouw, Kent W. NPJ Precis Oncol Article PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes varies widely in mCRPC and the impact of the less commonly altered genes on PARP inhibitor sensitivity is uncertain. We used functional approaches to directly test the impact of PALB2 and BARD1 loss on homologous recombination (HR) function and PARP inhibitor sensitivity in prostate cancer cell lines. PALB2 or BARD1 loss led to decreased HR function as measured by loss of radiation-induced Rad51 foci formation as well as decreased HR capacity in a cell-based reporter assay. PALB2 or BARD1 loss also significantly increased sensitivity to the PARP inhibitors olaparib and rucaparib across a panel of prostate cancer cell lines. These data support PALB2 and BARD1 loss as markers of clinically relevant PARP inhibitor sensitivity and highlight the potential to use functional approaches to complement and extend findings from clinical trials of targeted agents. Nature Publishing Group UK 2022-06-29 /pmc/articles/PMC9242979/ /pubmed/35768576 http://dx.doi.org/10.1038/s41698-022-00291-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Dillon, Kasia M. Bekele, Raie T. Sztupinszki, Zsofia Hanlon, Timothy Rafiei, Shahrzad Szallasi, Zoltan Choudhury, Atish D. Mouw, Kent W. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title | PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title_full | PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title_fullStr | PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title_full_unstemmed | PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title_short | PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer |
title_sort | palb2 or bard1 loss confers homologous recombination deficiency and parp inhibitor sensitivity in prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242979/ https://www.ncbi.nlm.nih.gov/pubmed/35768576 http://dx.doi.org/10.1038/s41698-022-00291-7 |
work_keys_str_mv | AT dillonkasiam palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT bekeleraiet palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT sztupinszkizsofia palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT hanlontimothy palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT rafieishahrzad palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT szallasizoltan palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT choudhuryatishd palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer AT mouwkentw palb2orbard1lossconfershomologousrecombinationdeficiencyandparpinhibitorsensitivityinprostatecancer |